President Trump signed an Executive Order on April 18, 2026 titled “Accelerating Medical Treatments for Serious Mental Illness,” directing the FDA to expedite its review of psychedelic compounds that have received Breakthrough Therapy designation.[1] The Order represents the most significant federal action on psychedelic medicine to date, but its ambitious scope, particularly its emphasis on ibogaine, raises serious questions for regulatory practitioners about whether political momentum can outrun clinical science.
The Executive Order at a Glance
The Executive Order rests on four pillars. First, it instructs the FDA Commissioner to issue Commissioner’s National Priority Vouchers to psychedelic drugs carrying Breakthrough Therapy designations that satisfy the criteria of the National Priority Voucher Program[2]. Second, it directs the FDA and DEA to establish a pathway for eligible patients to access investigational psychedelics, including ibogaine, under the federal Right to Try Act[3]. Third, it allocates $50 million through ARPA-H to match state investments in psychedelic research[4]. Fourth, it instructs the Attorney General to initiate rescheduling reviews upon successful completion of Phase 3 trials so that approved products can be rescheduled without delay[5].
FDA Commissioner Marty Makary announced that three psychedelic compounds would receive National Priority Vouchers in the week following the signing, marking the first time any psychedelic has been designated for the agency’s ultra-fast review track.[6]
The Priority Review Voucher: A Powerful but Double-Edged Tool
The Commissioner’s National Priority Voucher Program, first announced by the FDA in mid-2025, compresses regulatory review from the standard six-to-ten-month timeline to a target of one to two months.[7] The program was designed for breakthrough therapies addressing critical national health priorities, and the inaugural cohort of nine vouchers was issued in October 2025.[8]
The voucher’s significance for psychedelics cannot be overstated. For an industry that has struggled to attract and sustain private capital, particularly after the FDA’s August 2024 rejection of Lykos Therapeutics’ MDMA application for PTSD5, the prospect of a one-to-two-month review timeline fundamentally alters the risk calculus for sponsors.[9] Faster review means shorter cash-burn periods, earlier potential revenue, and a more compelling pitch to investors who have grown wary of regulatory uncertainty in this space.
However, as Professor I. Glenn Cohen of the Petrie-Flom Center at Harvard Law School has observed, the voucher may be a mixed blessing. While it accelerates the path to approval, some stakeholders worry that ultra-fast review may signal to payers and the public that the evidentiary basis for approval is weaker than for conventionally reviewed drugs.[10] For the first psychedelic to reach the market, this perception could be particularly damaging, as it could set an unfavorable precedent for reimbursement negotiations with CMS and private insurers. The Executive Order has less to say about this critical downstream question, though CMS Administrator Dr. Mehmet Oz indicated that the Center for Medicare and Medicaid Innovation is exploring new payment models for psychedelic therapies.[11]
There is also a separation-of-powers subtlety worth noting. The Order states that the Commissioner “shall provide” vouchers to qualifying psychedelics, using mandatory rather than permissive language. Yet the vouchers must still satisfy the criteria of the existing National Priority Voucher Program, which vests considerable discretion in the Commissioner.[12] In practice, the Order may function more as a strong political signal than a binding legal mandate, particularly given reports that the White House itself had previously blocked a psychedelic voucher earlier in 2026.[13]
Ibogaine: The Clinical Elephant in the Room
Of all the compounds implicated by the Executive Order, ibogaine presents the most formidable regulatory challenge. The Order mentions ibogaine by name twice,[14] in its policy statement and in the Right to Try provision, reflecting sustained advocacy by veterans’ groups, including Americans for Ibogaine and prominent supporters such as Congressman Morgan Luttrell and podcast host Joe Rogan.
The clinical promise of ibogaine is compelling. Preliminary open-label studies, including research led by Dr. Nolan Williams at Stanford, have reported dramatic reductions in PTSD symptoms and opioid withdrawal among veterans treated at clinics in Mexico.[15] Texas has allocated $50 million for ibogaine clinical research, and the federal government has committed to investing matching funds, as the Executive Order appears designed to support that initiative.[16]
Ibogaine can be dangerous for the heart. It blocks a specific channel in heart cells that helps regulate the heart’s electrical signals, which can disrupt the heart’s normal rhythm — a condition that can lead to potentially fatal irregular heartbeats.[17] In one observational study of 14 hospitalized patients receiving a relatively modest dose of ibogaine, the disturbance in heart rhythm was significant: half of the patients reached levels that doctors consider dangerously abnormal.[18] To place this in perspective, doctors assess heart rhythm disruption by measuring the “QT interval,” the time it takes for the heart muscle to contract and then electrically recharge itself before the next beat. The FDA raises concern when a drug delays this recharging process by even a small amount, but ibogaine caused disruptions nineteen times greater than that threshold.[19] Dr. Mark Haigney, a cardiologist at Walter Reed, has stated publicly that he has “never encountered a drug that prolongs the QT interval so profoundly.[20]
That said, opioid use disorder itself carries enormous mortality risk. Drug overdose is one of the leading causes of accidental death in the United States, having claimed nearly 1.3 million lives since 1999, with opioids involved in the majority of these preventable deaths.[21] Any honest risk-benefit analysis must compare ibogaine’s cardiac risk not against a healthy population but against a patient population already facing a life-threatening condition with limited treatment options. Methadone, the gold-standard OAT, is itself a significant QT-prolonging agent and carries its own overdose risk, yet it remains a first-line treatment.[22]
A 2022 systematic review by Köck and colleagues reported two fatalities across 24 supervised studies involving 705 participants, both attributable to identifiable protocol failures, including inadequate monitoring, unusually high doses, and undisclosed drug interactions.[23] The broader fatality data, by contrast, were concentrated in cases that did not meet the review’s inclusion criteria precisely because they occurred outside medical settings, suggesting that the cardiac risk, while serious, may be substantially mitigated by proper screening and monitoring protocols.[24]
The Right to Try Provision
The Right to Try provision adds another layer of complexity. Federal eligibility under the Right to Try Act requires completion of Phase 1 clinical trials. The Petrie-Flom Center analysis notes, however, ibogaine arguably has not met even this threshold, given the FDA’s longstanding resistance to domestic ibogaine research on safety grounds.[25] The Order’s instruction to create a Right to Try pathway for ibogaine thus creates a tension between the statute’s eligibility requirements and the clinical reality that ibogaine has not yet undergone Phase 1 clinical trials.
Phase 1 trials represent the first stage of formal human clinical testing and are primarily designed to assess safety, tolerability, and dosing rather than therapeutic efficacy. They typically enroll between 20 to 80 healthy volunteers or patients and can take one to two years to complete under normal circumstances. Given ibogaine’s cardiac safety profile, any Phase 1 program would need to be designed with extensive cardiac monitoring, careful dose-escalation protocols, and likely pre-screening for hERG channel sensitivity and baseline QTc intervals, all of which add time and complexity beyond a standard Phase 1 design.
Lessons from the MDMA Experience
The FDA’s 2024 rejection of Lykos Therapeutics’ New Drug Application for MDMA-assisted therapy for PTSD offers a cautionary precedent.[26] Despite two positive Phase 3 trials and Breakthrough Therapy designation, the FDA’s advisory committee voted against approval, citing functional unblinding, or the inability of participants to remain blinded to whether they received active drug or placebo, as well as concerns about the durability of treatment effects and potential selection bias from high rates of prior MDMA use among participants.[27]
These same methodological challenges will confront ibogaine developers with even greater force. Ibogaine produces a psychoactive experience lasting 10 to 30 hours, making functional unblinding virtually certain in any placebo-controlled trial. The entanglement of pharmacological effect and therapeutic context, what the FDA’s 2023 draft guidance on psychedelic drugs attempted to address, remains an unresolved regulatory paradigm problem that no executive order can bypass.
Conclusion
The Executive Order is a significant political milestone that reflects growing bipartisan recognition of the mental health crisis facing Americans, and veterans in particular. The deployment of National Priority Vouchers for psychedelic compounds is a potentially transformative regulatory mechanism. But the FDA’s statutory mandate to evaluate safety and efficacy under Section 505 of the FDCA remains unchanged. For ibogaine specifically, the gap between political enthusiasm and clinical evidence is wide. Responsible drug development will require rigorous Phase 1 dose-escalation studies with extensive cardiac monitoring, adequately powered Phase 3 trials with innovative designs to address functional unblinding, and honest reckoning with a cardiac safety signal that is, by any measure, among the most severe in modern psychopharmacology. The Executive Order opens doors, but science must still walk through them.
How Frier Levitt Can Help
Frier Levitt attorneys with expertise in psychedelic drug development and FDA regulatory law are available to assist clients with strategic advisory, regulatory compliance, drug development, and priority review voucher matters. Our team advises pharmaceutical companies, investors, and emerging therapeutics developers on navigating complex FDA approval pathways, clinical development strategies, and evolving regulatory frameworks impacting psychedelic and other novel therapies. We also provide guidance on risk mitigation, enforcement trends, and positioning products for successful commercialization in a rapidly developing regulatory landscape.
[1] Exec. Order, Accelerating Medical Treatments for Serious Mental Illness (Apr. 18, 2026), https: /www.whitehouse.gov/presidential-actions/2026/04/accelerating-medical-treatments-for-serious-mental-illness/.
[2] Ibid.
[3] Id.
[4] Id.
[5] Id.
[6]“Trump signs order fast tracking review of psychedelics for mental health disorders,” NPR (Apr. 18, 2026), https: /www.npr.org/2026/04/18/nx-s1-5789859/psychedelic-treatments-mental-health.
[7] “Developments in Psychedelic Regulation for COMP360,” Psychiatric Times (Mar. 2026), https: /www.psychiatrictimes.com/view/developments-in-psychedelic-regulation-for-comp360.
[8] “FDA Awards First-Ever National Priority Vouchers to Nine Sponsors” (Oct. 16, 2025), https: /www.fda.gov/news-events/press-announcements/fda-awards-first-ever-national-priority -vouchers-nine-sponsors.
[9] “FDA rejects MDMA, disappointing drugmaker Lykos and psychedelics industry,” NPR (Aug. 9, 2024), https: /www.npr.org/sections/shots-health-news/2024/08/09/nx-s1-5068634/mdma-therapy -fda-decision-ptsd-psychedelic-treatment.
[10] Glenn Cohen & Mason Marks, “A New Executive Order on Psychedelics: Q&A,” Petrie-Flom Center, Harvard Law School (Apr. 18, 2026), https: /petrieflom.law.harvard.edu/2026/04/18/a-new-executive-order-on-psychedelics-q-a-with-i-glenn-cohen-and-mason-marks/.
[11] “How Trump is pushing psychedelics reform through the health agencies,” STAT News (Apr. 18, 2026), https: /www.statnews.com/2026/04/18/psychedelics-ptsd-mental-health-research-boost-from-trump-executive-order/.
[12] Ibid.
[13] Id.
[14] Id. (1)
[15] “Federal research into psychedelic drug ibogaine to treat PTSD may soon be reality,” CBS 8 (Apr. 2026), https://www.cbs8.com/article/news/local/federal-study-into-psychedelic-drug-ibogaine-to-treat-ptsd-may-soon-be-reality/509-9331180a-3e4f-4a7e-bd22-0e0a9e382981.
[16] Id.(10)
[17] Knijver, T., et al., “Safety of ibogaine administration in detoxification of opioid-dependent individuals,” Addiction (2022), PMC 9292417.
[18] Id.(10)
[19] “Ibogaine long shot for FDA approval, heart expert warns Kentucky opioid commission,” Kentucky Lantern (Oct. 23, 2023), https: /kentuckylantern.com/2023/10/23/ibogaine-long-shot-for-fda-approval-heart-expert-warns-kentucky -opioid-commission/.
[20] Ibid.
[21]“2024 Opioid Overdose Daa Report: Key Trends and Insights” Overdoes Lifeline; Updated September 29, 2025. https://www.overdoselifeline.org/news/2024-opioid-overdose-data-report-key-trends-and-insights/
[22] Paknahad, M.H. et al., “QTc prolongation and torsades de pointes (TdP) in individuals undergoing methadone maintenance treatment (MMT): A systematic review and meta-analysis,” Medicine (Baltimore). 2025 Oct 24;104(43). https://pmc.ncbi.nlm.nih.gov/articles/PMC12558210/.
[23] Heink, A., et al., systematic review cited in Wikipedia, Ibogaine (2022) (documenting 27 deaths across 24 studies of 705 participants).
[24] Ibid.
[25] Id.(10)
[26] “FDA rejects MDMA, disappointing drugmaker Lykos and psychedelics industry,” NPR (Aug. 9, 2024), https: /www.npr.org/sections/shots-health-news/2024/08/09/nx-s1-5068634/mdma-therapy -fda-decision-ptsd-psychedelic-treatment.
[27] “FDA’s Decision: Why Lykos’ MDMA for PTSD NDA Was Rejected,” Psychedelic Support (Aug. 2024), https: /psychedelic.support/resources/fda-decision-lykos-ptsd-mdma-nda-rejected/
Senior Associate
